A plain language summary of atezolizumab compared with single-agent chemotherapy in participants with non-small cell lung cancer who should not receive platinum-based chemotherapy (the IPSOS study)

作者
Siow Ming Lee,Christian Klaus Jochen Schulz,Anne‐Marie Baird,Kumar Prabhash,Dariusz Mirosław Kowalski,Aleksandra Szczęsna,Baohui Han,Achim Rittmeyer,Toby Talbot,David Vicente,Raffaele Califano,Diego Luigi Cortinovis,Anh Tuan Le,Dingzhi Huang,Geoffrey Liu,Federico Cappuzzo,Jessica Reyes Contreras,Martin Reck,Ramón Palmero,Milena Perez Mak
出处
期刊:Future Oncology [Future Medicine]
卷期号:21 (14): 1725-1734
标识
DOI:10.1080/14796694.2025.2500915
摘要

Plain Language SummaryWhat is this summary about?This plain language summary reports the results of the IPSOS clinical study. This study looked at treatment with atezolizumab (a type of immunotherapy) compared with single-agent chemotherapy (1 chemotherapy drug; either vinorelbine or gemcitabine) in participants receiving their first treatment for advanced or metastatic non-small cell lung cancer (NSCLC).People with advanced or metastatic NSCLC are often treated with platinum-based chemotherapy, which is a combination of 2 drugs. However, a doctor may decide that some people are not suitable candidates for platinum-based chemotherapy because they are too weak, or they are older and have other medical conditions. These people who should not receive platinum-based chemotherapy are often treated with 1 chemotherapy drug (single-agent chemotherapy) instead.People who are weaker, older, or have other medical problems are often not allowed to participate in clinical trials for new medicines. Therefore, these patients are not well represented in clinical trials. The IPSOS study focused on these under-represented patients.The IPSOS study compared how well atezolizumab worked compared with single-agent chemotherapy (vinorelbine or gemcitabine) in participants who should not receive platinum-based chemotherapy.Researchers collected information about the health of participants for an average of more than 3 years after starting treatment.What were the results?Compared with single-agent chemotherapy, atezolizumab improved how long participants lived after starting treatment. After 2 years, the percentage of participants still alive was twice as high in the atezolizumab group (24%) compared with the chemotherapy group (12%), despite over 50% of patients in the chemotherapy group who were still alive at 2 years receiving subsequent immunotherapy. Throughout their treatment, participants in the atezolizumab group reported no change in their health and ability to function and enjoy life, while participants in the chemotherapy group reported worsening in some of these measures. Compared with single-agent chemotherapy, atezolizumab was associated with a similar rate of serious side effects (those that were life-threatening, needed hospital care, or caused lasting problems or death) related to treatment and half the rate of severe side effects (those considered medically important by a person’s doctor; also called ‘Grade 3, 4, or 5’) related to treatment.What do the results of the study mean?Atezolizumab is now approved by the European Medicines Agency and can be used as a first treatment for people with advanced or metastatic NSCLC who aren’t able to receive platinum-based chemotherapy.This is an abstract of the Plain Language Summary of Publication article.View the full Plain Language Summary PDF of this article to read the full-text

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
猪可以搞科研吗完成签到,获得积分10
1秒前
小熊维尼完成签到,获得积分10
1秒前
好彭友_RSRS完成签到,获得积分10
1秒前
Adler完成签到,获得积分10
1秒前
FAN完成签到 ,获得积分10
1秒前
2秒前
相由心生完成签到,获得积分10
2秒前
义气的巨人完成签到,获得积分10
2秒前
果儿完成签到,获得积分10
2秒前
realtimes完成签到,获得积分10
2秒前
乌漆嘛黑完成签到,获得积分10
2秒前
PNS发布了新的文献求助10
2秒前
su完成签到,获得积分10
2秒前
小宋完成签到,获得积分10
3秒前
Yuson_L发布了新的文献求助30
3秒前
glacierflame完成签到,获得积分10
3秒前
yy完成签到,获得积分10
3秒前
科研通AI6.4的应助被jr采纳,获得10
3秒前
3秒前
77发布了新的文献求助10
4秒前
4秒前
bjy完成签到,获得积分10
5秒前
5秒前
yan完成签到,获得积分10
5秒前
欢喜新梅完成签到,获得积分10
5秒前
锈了的xuebxuebi雪碧完成签到,获得积分10
5秒前
5秒前
若冰完成签到,获得积分10
5秒前
WUXIN完成签到,获得积分10
5秒前
6秒前
greenren完成签到,获得积分10
6秒前
唐糖完成签到,获得积分10
6秒前
脑洞疼的应助被小繁采纳,获得10
6秒前
连续流工艺技术完成签到,获得积分10
6秒前
欢呼妙菱完成签到,获得积分10
6秒前
香蕉觅云的应助被忧郁觅山采纳,获得10
6秒前
zhongjr_hz完成签到,获得积分10
6秒前
张玖完成签到,获得积分10
7秒前
8秒前
屹舟完成签到,获得积分10
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180189
求助须知:如何正确求助?哪些是违规求助? 9570320
关于积分的说明 21810161
捐赠科研通 7776320
什么是DOI,文献DOI怎么找? 3433267
关于科研通互助平台的介绍 2557483
邀请新用户注册赠送积分活动 2479039